Ocaperidone
From Wikipedia, the free encyclopedia
 |
|
| Names | |
|---|---|
| IUPAC name
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
|
|
| Identifiers | |
| 129029-23-8 | |
| ChemSpider | 64451 |
| 46 | |
| Jmol 3D image | Interactive graph |
| KEGG | D02675 |
| MeSH | C072259 |
| PubChem | 71351 |
|
|
|
|
| Properties | |
| C24H25FN4O2 | |
| Molar mass | 420.49 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
| Infobox references | |
Ocaperidone (also R 79598) is a benzisoxazole antipsychotic.[1] It was initially developed by Janssen, later licensed to French laboratory Neuro3D and then acquired in 2007 by German company Evotec. Its testing was abandoned after phase II trials, as of 22 February 2010.[2]
References[edit]
- ^ Leysen, JE; Janssen, PM; Gommeren, W; Wynants, J; Pauwels, PJ; Janssen, PA (1992). "In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone". Molecular Pharmacology 41 (3): 494–508. PMID 1372084.
- ^ "Ocaperidone — AdisInsight". Adis Insight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 10 December 2015.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
